tetano
Editor, Senior Moderator
Oncologist
. 2023 Feb 28;oyad003.
doi: 10.1093/oncolo/oyad003. Online ahead of print.
The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
Idan Cohen[SUP] 1 [/SUP], Salvatore Campisi-Pfinto[SUP] 2 [/SUP], Orit Rozenberg[SUP] 3 [/SUP], Raul Colodner[SUP] 3 [/SUP], Gil Bar-Sela[SUP] 1 4 [/SUP]
Affiliations
Abstract
Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose. Three groups of patients were included in the study: those who received 3rd-BNT162b2-dose and had no breakthrough infection (control), those who received 3rd-BNT162b2-dose and had the breakthrough infection, and those who received the 4th-BNT162b2-dose and had no breakthrough infection. Anti-SARS-CoV-2 immunoglobulin-G (IgG) levels of the control group exhibited a rapid decrease over time, whereas IgG titers of patients with breakthrough-infections or patients vaccinated with the 4th-BNT162b2-dose were considerably elevated, consistent with the capacity of the second booster to induce anti-SARS-CoV-2 IgG levels. Additionally, oncology patients' humoral immune response was significantly greater after breakthrough-infection than in response to the 4th dose of BNT162b2.
Keywords: BNT162b2 vaccine; SARS-CoV-2; cancer patient.
. 2023 Feb 28;oyad003.
doi: 10.1093/oncolo/oyad003. Online ahead of print.
The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
Idan Cohen[SUP] 1 [/SUP], Salvatore Campisi-Pfinto[SUP] 2 [/SUP], Orit Rozenberg[SUP] 3 [/SUP], Raul Colodner[SUP] 3 [/SUP], Gil Bar-Sela[SUP] 1 4 [/SUP]
Affiliations
- PMID: 36856804
- DOI: 10.1093/oncolo/oyad003
Abstract
Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose. Three groups of patients were included in the study: those who received 3rd-BNT162b2-dose and had no breakthrough infection (control), those who received 3rd-BNT162b2-dose and had the breakthrough infection, and those who received the 4th-BNT162b2-dose and had no breakthrough infection. Anti-SARS-CoV-2 immunoglobulin-G (IgG) levels of the control group exhibited a rapid decrease over time, whereas IgG titers of patients with breakthrough-infections or patients vaccinated with the 4th-BNT162b2-dose were considerably elevated, consistent with the capacity of the second booster to induce anti-SARS-CoV-2 IgG levels. Additionally, oncology patients' humoral immune response was significantly greater after breakthrough-infection than in response to the 4th dose of BNT162b2.
Keywords: BNT162b2 vaccine; SARS-CoV-2; cancer patient.